Keyphrases
Epidermal Growth Factor Receptor
100%
Lung Cancer
100%
Receptor-mediated Endocytosis
100%
Novel Therapeutic Targets
100%
Gefitinib
100%
Wild-type Epidermal Growth Factor Receptor
100%
Rab25
42%
Cell Viability
28%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
28%
Apoptotic Cell Death
14%
Knockdown
14%
Differentially Expressed
14%
Poor Prognosis
14%
Therapeutic Efficacy
14%
Lung Cancer Patients
14%
EGFR mutation
14%
Lung Cancer Cell Lines
14%
Therapeutic Target
14%
Patient Selection
14%
Epidermal Growth Factor Receptor Signaling
14%
Lung Cancer Cells
14%
Rational Therapeutics
14%
Potential Molecular Mechanism
14%
Oncogenic Alterations
14%
Lung Cancer Model
14%
Medicine and Dentistry
Lung Cancer
100%
Endocytosis
100%
Epidermal Growth Factor Receptor
100%
Gefitinib
53%
In Vitro
15%
Cell Viability
15%
Epidermal Growth Factor Receptor Kinase Inhibitor
15%
Cancer Cell
7%
Programmed Cell Death
7%
Cancer Model
7%
Combination Therapy
7%
Lung Cancer Cell Line
7%
Biochemistry, Genetics and Molecular Biology
Wild Type
100%
Epidermal Growth Factor Receptor
100%
Endocytosis
100%
Gefitinib
46%
Cancer Cell
13%
Cell Viability
13%
Receptor Tyrosine Kinase Inhibitors
13%
Apoptosis
6%
Pharmacology, Toxicology and Pharmaceutical Science
Epidermal Growth Factor Receptor
100%
Lung Cancer
100%
Gefitinib
53%
Cell Viability
15%
Epidermal Growth Factor Receptor Kinase Inhibitor
15%
Cancer Model
7%
Combination Therapy
7%